GSK plc (NYSE:GSK) Shares Acquired by London & Capital Asset Management Ltd

London & Capital Asset Management Ltd boosted its stake in GSK plc (NYSE:GSK) by 13.3% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 33,020 shares of the pharmaceutical company’s stock after acquiring an additional 3,883 shares during the period. London & Capital Asset Management Ltd’s holdings in GSK were worth $1,224,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in the stock. Royal Bank of Canada increased its stake in GSK by 255.5% during the second quarter. Royal Bank of Canada now owns 7,690,026 shares of the pharmaceutical company’s stock valued at $274,071,000 after purchasing an additional 5,526,736 shares during the last quarter. Arrowstreet Capital Limited Partnership increased its stake in GSK by 32.5% during the first quarter. Arrowstreet Capital Limited Partnership now owns 9,621,370 shares of the pharmaceutical company’s stock valued at $419,107,000 after purchasing an additional 2,362,274 shares during the last quarter. Goldman Sachs Group Inc. grew its position in shares of GSK by 48.3% during the first quarter. Goldman Sachs Group Inc. now owns 7,113,039 shares of the pharmaceutical company’s stock worth $309,844,000 after acquiring an additional 2,316,204 shares during the last quarter. Nomura Holdings Inc. bought a new position in shares of GSK during the fourth quarter worth about $73,232,000. Finally, FMR LLC grew its position in shares of GSK by 7.7% during the third quarter. FMR LLC now owns 18,099,513 shares of the pharmaceutical company’s stock worth $656,107,000 after acquiring an additional 1,291,161 shares during the last quarter. 15.74% of the stock is owned by institutional investors and hedge funds.

GSK Price Performance

GSK traded up $0.12 on Monday, reaching $40.78. The company had a trading volume of 585,903 shares, compared to its average volume of 3,498,704. The company has a fifty day moving average of $42.09 and a 200-day moving average of $38.70. The company has a market capitalization of $84.51 billion, a P/E ratio of 13.55, a PEG ratio of 1.86 and a beta of 0.64. The company has a current ratio of 0.88, a quick ratio of 0.62 and a debt-to-equity ratio of 1.19. GSK plc has a one year low of $33.33 and a one year high of $43.84.

GSK (NYSE:GSK) last issued its quarterly earnings results on Wednesday, January 31st. The pharmaceutical company reported $0.72 earnings per share for the quarter, missing analysts’ consensus estimates of $0.76 by ($0.04). GSK had a net margin of 16.24% and a return on equity of 51.45%. The business had revenue of $10 billion during the quarter, compared to analyst estimates of $9.79 billion. As a group, equities research analysts anticipate that GSK plc will post 4.03 earnings per share for the current year.

GSK Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Thursday, April 11th. Shareholders of record on Friday, February 23rd were issued a $0.3564 dividend. This represents a $1.43 dividend on an annualized basis and a yield of 3.50%. This is an increase from GSK’s previous quarterly dividend of $0.34. The ex-dividend date of this dividend was Thursday, February 22nd. GSK’s dividend payout ratio is presently 52.82%.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on GSK shares. Morgan Stanley started coverage on shares of GSK in a research report on Tuesday, January 23rd. They set an “equal weight” rating for the company. Citigroup upgraded shares of GSK from a “neutral” rating to a “buy” rating in a research report on Tuesday, February 13th. Guggenheim upgraded shares of GSK from a “neutral” rating to a “buy” rating in a research report on Monday, March 4th. Finally, Jefferies Financial Group upgraded shares of GSK from a “hold” rating to a “buy” rating in a research report on Wednesday, January 3rd. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, GSK currently has an average rating of “Moderate Buy”.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.